Skip to main content
SpringerLink
Log in

Pharmacovigilance in Pediatrics

Current Challenges

  • Editorial
  • Published:
Pediatric Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. European Commission. Regulation (EC) No 1ss901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004 [online]. Available from URL: http://eur-lex.europa.eu/LexUriServ/site/en/oj/2006/l_378/l_37820061227en00010019.pdf [Accessed 2011 Aug 9]

  2. Senate and House of Representatives of the United States of America. Pediatric Research Equity Act of 2003 [online]. Available from URL: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM077853.pdf [Accessed 2011 Sept 17]

  3. The Uppsala Monitoring Centre. Safety monitoring of medicinal products: guidelines for setting up and running a pharmacovigilance centre. Uppsala: WHO Collaborating Centre for International Drug Monitoring, 2000

    Google Scholar 

  4. Choonara I. Paediatric pharmacovigilance. Paed Perinat Drug Ther 2006; 7(2):50–3

    Article  Google Scholar 

  5. Impicciatore P, Choonara I, Clarkson A, et al. Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies. Br J Clin Pharmacol 2001; 52(1): 77–83

    Article  PubMed  CAS  Google Scholar 

  6. Clavenna A, Bonati M. Adverse drug reactions in childhood: a review of prospective studies and safety alerts. Arch Dis Child 2009; 94(9): 724–8

    Article  PubMed  CAS  Google Scholar 

  7. Rashed A, Wong I, Cranswick N, et al. Adverse Drug Reactions in Children-International Surveillance and Evaluation (ADVISE): a multicentre cohort study. Drug Saf. In press

  8. Gallagher RM, Bird KA, Mason JR, et al. Adverse drug reactions causing admission to a paediatric hospital: a pilot study. J Clin Pharm Ther 2011; 36(2): 194–9

    Article  PubMed  CAS  Google Scholar 

  9. Verhamme K, Bonifazi F, Ceci A, et al. Adverse drug reactions reporting in children. Pharmaceutic Policy Law 2009; (11): 89–99

    Google Scholar 

  10. Star K, Noren GN, Nordin K, et al. Suspected adverse drug reactions reported for children worldwide: an exploratory study using VigiBase. Drug Saf 2011; 34(5): 415–28

    Article  PubMed  Google Scholar 

  11. European Medicine Agency. Paediatric Committee (PDCO) monthly report, September 2011 [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Committee_meeting_report/2011/09/WC500112091.pdf [Accessed 2011 Sep 17]

  12. Olski TM, Lampus SF, Gherarducci G, et al. Three years of paediatric regulation in the European Union. Eur J Clin Pharmacol 2011; 67(3): 245–52

    Article  PubMed  Google Scholar 

  13. European Commission CORDIS. Seventh Framework Programme (FP7) [online]. Available from URL: http://cordis.europa.eu/fp7/home_en.html [Accessed 2011 Sep 23]

  14. Paediatric Medicines Section, European Medicine Agency. Report to the European Commission. EMA/163613/2011 11 A.D [online]. Available from URL: http://ec.europa.eu/health/files/paediatrics/2011_report_art50l.pdf [Accessed 2011 Sep 6]

  15. ADDUCE: Attention deficit hyperactivity disorder drugs use chronic effects [online]. Available from URL: http://adhd-adduce.org [Accessed 2011 Aug 1]

  16. Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf 2006; 29(5): 385–96

    Article  PubMed  Google Scholar 

  17. Carleton B, Poole R, Smith M, et al. Adverse drug reaction active surveillance: developing a national network in Canada’s children’s hospitals. Pharma-coepidemiol Drug Saf 2009; 18(8): 713–21

    Article  Google Scholar 

  18. Clarkson A, Conroy S, Burroughs KCI. Surveillance for adverse drug reactions in children: a paediatric regional monitoring centre. Paediatr Perinat Drug Ther 2004; 6: 20–3

    Article  Google Scholar 

  19. Menniti-Ippolito G, Raschetti R, Da CR, et al. Active monitoring of adverse drug reactions in children. Italian Paediatric Pharmacosurveillance Multi-center Group. Lancet 2000; 355(9215): 1613–4

    Article  PubMed  CAS  Google Scholar 

  20. Ortega A, Aguinagalde A, Lacasa C, et al. Efficacy of an adverse drug reaction electronic reporting system integrated into a hospital information system. Ann Pharmacother 2008; 42(10): 1491–6

    Article  PubMed  Google Scholar 

  21. Sanz EJ, De-las-Cuevas C, Kiuru A, et al. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet 2005; 365(9458): 482–7

    PubMed  CAS  Google Scholar 

  22. European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP®) [online]. Available from URL: http://www.encepp.eu [Accessed 2011 Aug 9]

  23. Dormann H, Muth-Selbach U, Krebs S, et al. Incidence and costs of adverse drug reactions during hospitalisation: computerised monitoring versus stimulated spontaneous reporting. Drug Saf 2000; 22(2): 161–8

    Article  PubMed  CAS  Google Scholar 

  24. Egger T, Dormann H, Ahne G, et al. Identification of adverse drug reactions in geriatric inpatients using a computerised drug database. Drugs Aging 2003; 20(10): 769–76

    Article  PubMed  CAS  Google Scholar 

  25. Evans RS, Pestotnik SL, Classen DC, et al. Development of a computerized adverse drug event monitor. Proc Annu Symp Comput Appl Med Care 1991; 23–7

    Google Scholar 

  26. Jha AK, Kuperman GJ, Teich JM, et al. Identifying adverse drug events: development of a computer-based monitor and comparison with chart review and stimulated voluntary report. J Am Med Inform Assoc 1998; 5(3): 305–14

    Article  PubMed  CAS  Google Scholar 

  27. Seger AC, Jha AK, Bates DW. Adverse drug event detection in a community hospital utilising computerised medication and laboratory data. Drug Saf 2007; 30(9): 817–24

    Article  PubMed  CAS  Google Scholar 

  28. Haffner S, von Laue N, Wirth S, et al. Detecting adverse drug reactions on paediatric wards: intensified surveillance versus computerised screening of laboratory values. Drug Saf 2005; 28(5): 453–64

    Article  PubMed  Google Scholar 

  29. Neubert A, Dormann H, Weiss J, et al. Are computerised monitoring systems of value to improve pharmacovigilance in paediatric patients? Eur J Clin Pharmacol 2006; 62(11): 959–65

    Article  PubMed  Google Scholar 

  30. Takata GS, Mason W, Taketomo C, et al. Development, testing, and findings of a pediatric-focused trigger tool to identify medication-related harm in US children’s hospitals. Pediatrics 2008; 121(4): e927–35

    Article  PubMed  Google Scholar 

  31. Matlow AG, Cronin CM, Flintoft V, et al. Description of the development and validation of the Canadian Paediatric Trigger Tool. BMJ Qual Saf 2011; 20(5): 416–23

    Article  PubMed  Google Scholar 

  32. European Commission. Regulation (EU) No 1235/2010 of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance of medicinal products for human use, Regulation (EC) No 726/2004 laying down Community procedures for the authorization and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, and Regulation (EC) No 1394/2007 on advanced therapy medicinal products. Official Journal of the European Union 2010: L 348/1–16 [online]. Available from URL: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2010:348:0001:0016:en:pdf [Accessed 2011 Sept 6]

  33. European Commission. FP7 Cooperation Work Programme: Health-2012, European Commission C(2011)5068 of 19 July 2011 [online]. Available from URL: http://ec.europa.eu/research/fp7/pdf/wp2012/wp2012_cooperation_health.pdf [Accessed 2011 Sep 17]

Download references

Acknowledgments

No sources of funding were used to prepare this editorial. The author has no conflicts of interest that are directly relevant to the content of this editorial.

Author information

Authors and Affiliations

  1. Department of Paediatric and Adolescent Medicine, University Hospital Erlangen, Loschgestr. 15, 91054, Erlangen, Germany

    Antje Neubert

Authors
  1. Antje Neubert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Antje Neubert.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Neubert, A. Pharmacovigilance in Pediatrics. Pediatr Drugs 14, 1–5 (2012). https://doi.org/10.2165/11596590-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11596590-000000000-00000

Search

Navigation